NGL Fine-Chem Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
NGLFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.8 pts more than Nifty Microcap 250 and 11.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NGL Fine-Chem Limited reported strong full-year results for FY2026. Consolidated revenue from operations grew 36% to Rs. 50,095.47 lakhs from Rs. 36,825.67 lakhs in FY2025. Net profit after tax surged 128% to Rs. 4,812.67 lakhs from Rs. 2,112.43 lakhs. On standalone basis, revenue grew 36% to Rs. 48,877.38 lakhs and PAT jumped 130% to Rs. 4,163.22 lakhs. The Board recommended a final dividend of Rs. 1.75 per share (Rs. 108.12 lakhs total). The statutory auditors issued an unmodified (clean) opinion with no qualifications. Capital work-in-progress increased significantly to Rs. 9,456.72 lakhs from Rs. 4,972.58 lakhs, indicating ongoing expansion. The company reappointed two key directors subject to shareholder approval.
The strong 36% revenue growth and 128% PAT growth are positive signals for shareholders. The clean audit report and dividend recommendation reinforce financial stability. The significant increase in capital work-in-progress suggests the company is investing for future growth in the pharmaceuticals segment.